<p>In part one of a 3-part series on the Nitrosamine crisis, Dr. Andrew Teasdale of AstraZeneca discusses regulatory expectations, reporting requirements, and minimizing risk relative to solvent contamination.</p>

In part one of a 3-part series on the Nitrosamine crisis, Dr. Andrew Teasdale of AstraZeneca discusses regulatory expectations, reporting requirements, and minimizing risk relative to solvent contamination.

Episode 8: The Nitrosamine Crisis: Controlling Risk by Leveraging MLCM Principles – Part 1

New guidelines from the USP and ICH will facilitate and accelerate adoption of Method Lifecycle Management (MLCM.) Experts will explore a variety of topics to help you understand and adopt MLCM including: key concepts like the Analytical Target Profile, regulatory changes that will impact your workflow, and case studies exploring the application and advantages of MLCM.

Share Episode 8: The Nitrosamine Crisis: Controlling Risk by Leveraging MLCM Principles – Part 1

Sign up to save your podcasts

Episode 8: The Nitrosamine Crisis: Controlling Risk by Leveraging MLCM Principles – Part 1

Episode 8: The Nitrosamine Crisis: Controlling Risk by Leveraging MLCM Principles – Part 1